Clinical trial · Observational
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 Antibody Responses in Immunosuppressed People (The MELODY Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease, and treatment characteristics that influence antibody status. 2. If the detection of antibodies inversely correlates with subsequent risk of severe acute respiratory syndrome coronavirus-2 infection and/or severity of disease in immunosuppressed people.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Autoimmune Diseases | — | UNRESOLVED | — |
| Haematological Malignancies | — | UNRESOLVED | — |
| Solid Organ Transplant Recipients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| self-administered lateral flow assays | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Solid organ transplant patients
- description
- Patients who have received a solid organ transplant and who have received at least 3 doses of Covid-19 vaccine
- interventionNames
- Diagnostic Test: self-administered lateral flow assays
- label
- Rare autoimmune diseases
- description
- Patients with a rare autoimmune disease who have received at least 3 doses of Covid-19 vaccine
- interventionNames
- Diagnostic Test: self-administered lateral flow assays
- label
- Blood cancer
- description
- Patients with acute myeloid and lymphoid blood cancers who have received at least 3 doses of Covid-19 vaccine.
- interventionNames
- Diagnostic Test: self-administered lateral flow assays
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: Adults and young people over 12 years of age, and are classified as being part of one of the following patient groups: 1. A solid organ transplant recipient (n=12,000) 2. Patients with a rare autoimmune disease (n=12,000) 3. Patients with lymphoid malignancies (n=12,000) - Exclusion Criteria: \-
References
Publications (0)
Data not yet available